Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Bio-Techne (TECH) to $61 from $62 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne Reports Q1 FY2026 Earnings with Strategic Focus
- Bio-Techne’s Earnings Call: Mixed Sentiment Amid Growth and Challenges
- Positive Long-Term Outlook for Bio-Techne Amid Short-Term Challenges
- Bio-Techne: Strong Profitability and Growth Potential Amidst Challenges Justify Buy Rating
- Bio-Techne Reports Q1 2026 Revenue and EPS Growth